Cerus Stock Earnings Reports

Cerus reported a strong start to 2026 with Q1 product revenue of $53.7M, up 24% year-over-year, driven by platelet growth and accelerating U.S. INTERCEPT fibrinogen complex (IFC) demand. Management raised full-year 2026 product revenue guidance to $227M–$231M and IFC guidance to $22M–$24M (IFC growth of ~30%–40% year-over-year expected). North America contributed ~70% of Q1 product revenue; EMEA also performed well (notably France and Belgium) with FX tailwinds. Key commercial drivers include the Blood Centers of America (BCA) group purchasing agreement aiding U.S. expansion, renewed multiyear contract with the French blood service (EFS), continued international rollout of the INT-200 illuminator, and increasing kit-based IFC sales. Financially, total revenue rose 23% (including government contract revenue), Q1 gross margin declined to 52% (expected to remain in the low-50s for 2026 due to inflation, FX and tariffs), GAAP net loss narrowed to $1.6M, and adjusted EBITDA was positive $4M — the eighth consecutive quarter of positive adjusted EBITDA. Cash was $80.4M at quarter end, and working capital build supported inventory for growth. Clinical and regulatory catalysts ahead: INT-200 PMA submission to FDA planned in Q2 2026 with a U.S. launch expected in H1 2027; INTERCEPT red blood cell program has Phase III RedeS enrollment complete with a readout expected in Q4 2026 and ANSM/CE Mark progress anticipated (potential commercial availability likely in H1 2027 timeframe). Leadership transition: long-time CEO Obi (William) Greenman is stepping to Chairman, and Vivek Jayaraman becomes CEO. Management emphasizes continued double-digit sustainable growth, innovation, and disciplined expense control with line of sight to GAAP profitability.